CRSP
CRSP
NASDAQ · Biotechnology

Crispr Therapeutics Ag

$48.56
-3.22 (-6.21%)
As of Nov 5, 9:55 PM ET ·
Financial Highlights (FY 2026)
Revenue
3.55M
Net Income
-589,192,914
Gross Margin
—
Profit Margin
-16,569.8%
Rev Growth
+43.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 54.8% 54.8%
Operating Margin -18,933.6% -17,040.3% -11.6% -11.4%
Profit Margin -16,569.8% -15,741.3% -12.2% -11.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.55M 2.48M 1.10B 1.10B
Gross Profit — — 601.13M 602.78M
Operating Income -672,687,402 -423,340,089 -127,445,861 -125,238,954
Net Income -589,192,914 -370,794,785 -133,819,624 -129,413,867
Gross Margin — — 54.8% 54.8%
Operating Margin -18,933.6% -17,040.3% -11.6% -11.4%
Profit Margin -16,569.8% -15,741.3% -12.2% -11.8%
Rev Growth +43.0% +43.0% +24.0% +12.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.78B 1.51B
Total Equity — — 2.90B 2.79B
D/E Ratio — — 0.61 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -653,518,030 -434,124,976 -179,167,841 -179,074,292
Free Cash Flow — — -115,939,335 -83,372,083